Learn about the impact Gout has on patients and healthcare in our interview with noted rheumatologist, Dr. N. Lawrence Edwards 

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout and non-alcoholic steatohepatitis (NASH) for which there are no effective treatments.

Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2023. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease.

Latest News from Atom Bioscience

Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout
Atom Bioscience to Present at BIO CEO & Investor Conference on February 6, 2023, at the Marriott Marquis, New York City
Atom Bioscience Names Stanford University Professor Vibeke Strand, M.D., to its Scientific Advisory Board
Kidney Disease Among Top Contributors to Excess Death Risk in Veterans With Gout